Patent ID: 9545408
Date: 2017-01-17
CPC Classifications: A61K,A61P

Claim:
1. A kit for use in treating a skin infection of a mammal infected by a virus that causes disordered tissue, including a skin infection in prodromal stage and/or with blisters or lesions, the kit comprising: a systemic treatment composition formulated for systemic administration, including at least one of oral administration, subcutaneous administration, intramuscular administration, intravenous administration, intradermal administration, intrathecal administration, or epidural administration, the systemic treatment composition comprising an effective amount of a systemic anti-virus drug that, when systemically administered to a mammal in need thereof, provides systemic anti-viral activity and disrupts or inhibits virus replication systemically within the mammal, wherein the systemic anti-virus drug is selected from the group consisting of: aciclovir (2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6H-purin-6-one); pharmaceutically acceptable salts, phosphate esters, and acyl derivatives of aciclovir; aciclovir phosphate derivatives selected from the group consisting of: aciclovir amino acid ester derivatives selected from the group consisting of: aciclovir derivatives selected from the group consisting of: 3R-(3α,4β,5α)]-2-amino-1,9-dihydro-9-tetrahydro-4-hydroxy-5-(hydroxymethyl)-3-furanyl]-6H-purin-6-one; [3R-(3α,4β,5α)]-5-methyl-1-[tetrahydro-4-hydroxy-5-(hydroxymethyl)-3-furanyl]2,4(1H,3H)pyrimidinedione; [3R-(3α,4β,5α)]-4-amino-1-[tetrahydro-4-hydroxy-5-(hydroxymethyl)-3-furanyl]-2(1H)-pyrimidinone; and [3R-(3α,4β,5α)]-1-[tetrahydro-4-hydroxy-5-(hydroxymethyl)-3-furanyl]-2,4(1H,3H)pyrimidinedione; valaciclovir ((S)-2-[(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)methoxy]ethyl-2-amino-3-methylbutanoate); pharmaceutically acceptable salts, phosphate esters, and acyl derivatives of valaciclovir; valaciclovir derivatives selected from the group consisting of: 2-[(2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl N-[(benzyloxy)carbonyl]L-valinate; 2-[(2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valinate; 2-(2-Amino-1,6-dihydro-6-oxo-9H(purin-9-yl)methoxy)ethyl L-valinate hydrochloride monohydrate; 2-[(2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl N-[(benzyloxy)carbonyl]L-valinate; and 2-[(2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valinate hydrochloride monohydrate; penciclovir (2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-6,9-dihydro-3H-purin-6-one); pharmaceutically acceptable salts, phosphate esters, and acyl derivatives of penciclovir; penciclovir derivatives selected from the group consisting of: 2-Amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]-6H-purine; 2-Amino-6-chloro-9-[2-(2,2-dimethyl-1,3-dioxan-5-yl)ethyl]-purine; 9-[4-Hydroxy-3-(hydroxymethyl)but-1-yl]guanine; 9-(4-Acetoxy-3-acetoxymethylbut-1-yl)-2-amino-6-chloropurine; 7-(4-Acetoxy-3-acetoxymethylbut-1-yl)-2-amino-6-chloropurine; 9-(4-Hydroxy-3-hydroxymethylbut-1-yl)guanine, sodium salt; 9-(4-Hydroxy-3-hydroxymethylbut-1-yl)guanine, potassium salt; 2-Amino-6-chloro-9-(4-hydroxy-3-hydroxymethylbut-1-yl)purine hydrochloride; 2-Amino-9-(4-hydroxy-3-hydroxymethylbut-1-yl)-6-methoxypurine; 2-Amino-6-ethoxy-9-(4-hydroxy-3-hydroxymethylbut-1-yl)purine; 2-Amino-6-benzyloxy-9-(4-hydroxy-3-hydroxymethylbut-1-yl) purine; 2-Amino-9-(4-hydroxy-3-hydroxymethylbut-1-yl)-6-thiopurine; 2-Amino-6-azido-9-[2-(2,2-dimethyl-1,3-dioxan-5-yl)ethyl]-purine; 2,6-Diamino-9-[2-(2,2-dimethyl-1,3-dioxan-5-yl)ethyl]purine; 2,6-Diamino-9-(4-hydroxy-3-hydroxymethylbut-1-yl)purine; 9-(4-Acetoxy-3-acetoxymethylbut-1-yl)guanine; 9-(4-Propionyloxy-3-propionyloxymethylbut-1-yl)guanine; N2-Propionyl-9-(4-propionyloxy-3-propionyloxymethyl-but-1-yl)guanine; 9-(4-Hexanoyloxy-3-hexanoyloxymethylbut-1-yl)guanine; 9-(4-Formyloxy-3-formyloxymethylbut-1-yl)guanine; 9-[4-(N-Imidazolylcarbonyloxy)-3-(N-imidazolylcarbonyloxymethyl)-but-1-yl]guanine; N2-Monomethoxytrityl-9-(4-monomethoxytrityloxy-3-hydroxymethylbut-1-yl)guanine; N2-Monomethoxytrityl-9-(4-hydroxy-3-hydroxymethylbut-1-yl)-guanine; 9-(4-Pivalyloxy-3-pivalyloxymethylbut-1-yl)guanine; 9-(4-Acetoxy-3-hydroxymethylbut-1-yl)guanine; 9-(4-Benzoyloxy-3-hydroxymethylbut-1-yl)guanine; 9-(4-Hexanoyloxy-3-hydroxymethylbut-1-yl)guanine; 9-(4-Hexadecanoyloxy-3-hydroxymethylbut-1-yl)guanine; 9-(4-Hydroxy-3-hydroxymethylbut-1-yl)guanine 4′-phosphate, diammonium salt; N2-Acetyl-9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; N2-Hexanoyl-9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; 2-Amino-9-(4-hydroxy-3-hydroxymethylbut-1-yl)-6-isopropoxypurine; and 2-Amino-9-(4-hydroxy-3-hydroxymethylbut-1-yl)-6-phenoxypurine; famciclovir (2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate); pharmaceutically acceptable salts, phosphate esters, and acyl derivatives of famciclovir; famciclovir derivatives selected from the group consisting of: 2-amino-9-(4-hydroxy-3-hydroxymethylbut-1-yl)purine; 2-amino-9-(4-acetoxy-3-acetoxymethylbut-1-yl)purine; 2-amino-9-(4-acetoxy-3-hydroxymethylbut-1-yl)purine; 2-amino-9-(3-hydroxymethyl-4-methoxycarbonyloxybut-1-yl)purine; 2-amino-9-[2-(2,2-dimethyl-1,3-dioxan-5-yl)ethyl]purine; 2-amino-9-(4-propionyloxy-3-propionyloxymethylbut-1-yl)purine; 2-amino-9-(4-butyryloxy-3-hydroxymethylbut-1-yl)purine; 2-amino-9-(4-benzoyloxy-3-hydroxymethylbut-1-yl)purine; 2-amino-9-(4-hydroxy-3-hydroxymethylbut-1-yl)purine 4′-phosphate; and 2-amino-9-(4-hydroxy-3-hydroxymethylbut-1-yl)purine 4′:4″phosphate; ganciclovir (2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one); pharmaceutically acceptable salts, phosphate esters, and acyl derivatives of ganciclovir; cidofovir (({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid); pharmaceutically acceptable salts, phosphate esters, and acyl derivatives of cidofovir; adefovir ({[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}phosphonic acid); pharmaceutically acceptable salts, phosphate esters, and acyl derivatives of adefovir; tenofovir (({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl) phosphonic acid); pharmaceutically acceptable salts, phosphate esters, and acyl derivatives of tenofovir; and combinations thereof; and a topical treatment composition separate from the systemic treatment composition and formulated for topical administration to an infection site in order to kill viruses at the infection site without entering the bloodstream of the mammal, the topical treatment composition comprising benzalkonium chloride in an amount so as to kill viruses at the infection site and a tissue penetrating liquid carrier comprising water and an organic solvent that promotes penetration of the topical treatment composition into the infection site of the mammal and below the skin surface so as to allow the topical treatment composition to kill viruses at the infection site independent of the systemic anti-viral activity of the systemic anti-virus drug.